Exentis Knowledge Gmbh

Laxxon Medical Ag

Affiris Ag

Ac Immune Sa

Advantage Therapeutics, Inc.

Laxxon Medical Ag Exentis Knowledge Gmbh

Accanis Biotech F&e Gmbh & Co Kg

Achim Schneeberger

Klaus Kühne

Helmut Kerschbaumer

Srdan Vasic

Walter G Schmidt

Frank Mattner

Markus Mandler

Arne Von Bonin

Guenther Staffler

Wolfgang Zauner

Gergana Galabova

Andreas Mairhofer

Dorian Winter

Alexander Ruckdäschel

Sabine Schmidhuber

Jana Zimmermann

Martina Lutterova

Günther Staffler

Daniel Moldenhauer

The present invention relates to a method for producing a drug delivery system. The method comprises the steps of screen-printing a base paste, and curing the base paste. Furthermore, the method comprises the steps of screen-printing a first paste separate to the base paste, and curing the first paste.

Method for producing a drug delivery system

Disclosed is a method for vaccination against a self-antigen in a human patient wherein a dose with an effective amount of a self-antigen is administered to the patient to elicit a primary immune response, characterised in that the patient is subjected to a boost administration of said self-antigen, wherein the amount of the self-antigen in the dose for the boost administration is higher than the amount of the self-antigen in the dose used in the administration for the primary immune response.

Method for vaccination against a self-antigen in a human patient

A solid dosage form for active ingredient release can be a preparation for medical, dental or cosmetic purposes, and is preferably a tablet. The solid dosage form comprises a three-dimensional base body which comprises an active ingredient. The solid dosage form further comprises a portion having a structure forming a two-dimensional identifier, such as, for instance, a QR code.

Tablet having a two-dimensional identifier

The present invention relates to a drug delivery system, in particular for a controlled administration of one or more active pharmaceutical ingredients to a body, and further in particular for oral administration of one or more active pharmaceutical ingredients to a body. The system thereby comprises a base component soluble in body fluids and a separate first component soluble in body fluids. The first component thereby comprises a therapeutically effective amount of a first active pharmaceutical ingredient.

Drug delivery system

Disclosed is a method for the treatment of AD, wherein an immune stimulating pharmaceutical composition comprising an aluminium salt is administered to a patient having AD or having a risk to develop AD in an effective amount.

Treatment of Alzheimer's Disease (AD) with an aluminum salt

The invention discloses an aluminium salt for use in the treatment and prevention of dementias associated with &#x3b2;-amyloid deposition, preferably AD.

Treatment and prevention of alzheimer's disease (AD)

Treatment of alzheimer'S disease (AD) with an aluminum salt

The invention discloses aluminium oxyhydroxide for use in the treatment and prevention of AD.

Treatment of Alzheimer's disease (AD) with aluminum oxyhydroxide

Disclosed is a method for diagnosing Alzheimer's disease (AD) wherein A&#x3b2;-specific antibodies in a biological sample of a person that is suspected of having AD are detected comprising the following steps: &#x2014;contacting the sample with A&#x3b2;-aggregates or with particles having A&#x3b2;-aggregate like surfaces and allowing the A&#x3b2;-specific antibodies to bind to the A&#x3b2;-aggregates, and &#x2014;detecting the A&#x3b2;-specific antibodies bound to the A&#x3b2;-aggregates by a single particle detection technique, preferably by fluorescence activated cell sorting (FACS); and wherein the amount of A&#x3b2;-specific antibodies detected is compared with the amount in a sample of known AD status.

Method for diagnosing alzheimer's disease (AD)

Growing community of inventors

Vienna, Austria

Achim Schneeberger